Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Andrew William Pippas"'
Autor:
Ashlesha Patel, Ju-Whei Lee, Howard A. Zaren, Erika K Radeke, Rachel E. Lerner, Jami Aya Fukui, Della F. Makower, Deimante Tamkus, Kendrith M. Rowland, William M. Adler, Alyssa Throckmorton, Sharad A. Ghamande, Mary Helen Hackney, Andrew William Pippas, Rubina Qamar, David Cella, Michael Jordan Fisch, Lynne I. Wagner
Publikováno v:
Journal of Clinical Oncology. 40:1519-1519
1519 Background: Reproductive health (RH) needs of women newly diagnosed with cancer have been poorly addressed. RH management must be aligned with cancer treatment to optimize cancer survivorship. The primary objective of the EROS trial is to evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b147adf9d80df3f3e2c8fd03be00dfbf
https://doi.org/10.1200/jco.2022.40.16_suppl.1519
https://doi.org/10.1200/jco.2022.40.16_suppl.1519
Autor:
Benjamin Solomon, Alexander Drilon, Mihran Shirinian, Viola W. Zhu, D. Ross Camidge, Arkadiusz Z. Dudek, Nashat Y. Gabrail, Jessica J. Lin, Robert C. Doebele, Peter M. Anderson, Andrew William Pippas, Byoung Chul Cho, Misako Nagasaka, Lyudmila Bazhenova, Christina S. Baik, Shanna Stopatschinskaja
Publikováno v:
Journal of Clinical Oncology. 38:TPS9637-TPS9637
TPS9637 Background: Repotrectinib is a next-generation ROS1/TRK inhibitor with > 90-fold greater potency than crizotinib against ROS1 and > 100-fold greater potency than larotrectinib against TRK. Preclinical studies demonstrated inhibitory activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e1e9cfdf146eea53704056ffa2e0fb0
https://doi.org/10.1200/jco.2020.38.15_suppl.tps9637
https://doi.org/10.1200/jco.2020.38.15_suppl.tps9637
Autor:
Ian Chau, Johanna C. Bendell, Kerry Culm-Merdek, Jeeyun Lee, Jessicca Rege, Andrew William Pippas
Publikováno v:
Journal of Clinical Oncology. 38:TPS459-TPS459
TPS459 Background: The majority of gastric cancer (GC) patients fail to derive sufficient benefit from currently available therapies. Pembrolizumab received accelerated approval in 2017 as a third-line therapy in PD-L1 positive GC patients with an OR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::937c5a1adc457f15aaef51160e891147
https://doi.org/10.1200/jco.2020.38.4_suppl.tps459
https://doi.org/10.1200/jco.2020.38.4_suppl.tps459
Autor:
Aprille Belgrave, William G. Richards, Nancy M. Paris, James J. Burke, Sreekanth Reddy, Colleen Hope McDonough, Anand Jillella, Mark A. Taylor, Joni Short, Andrew William Pippas, Vamsi Kota, Howard A. Zaren, Guilherme Cantuaria, Melissa S. Dillmon, Geri Whitaker, Sharad A. Ghamande, Jayanthi Srinivasiah, Frederick M. Schnell, Andrew Emmons Green
Publikováno v:
Journal of Clinical Oncology. 36:e18651-e18651
e18651Background: Clinical trials promote excellence in cancer care but only 2 – 3 % of patients enroll on trials. 1Minorities who experience the greatest cancer burden are least likely to enroll, ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93b150d0b326da3e3ad74a75ef717929
https://doi.org/10.1200/jco.2018.36.15_suppl.e18651
https://doi.org/10.1200/jco.2018.36.15_suppl.e18651
Autor:
Shirin Khambata-Ford, Heinz-Josef Lenz, Philip Stella, Eric K. Rowinsky, Nozar Azarnia, Robert J. Mayer, Allen Lee Cohn, Eric Van Cutsem, David J. Mauro, Andrew William Pippas, B. Mirtsching, Zenta Tsuchihashi, Philip J. Gold
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(30)
Purpose This multicenter study evaluated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in metastatic colorectal carcinoma (CRC) refractory to irinotecan, oxaliplatin, and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76d19055690bdd3116db315b3ddde693
https://pubmed.ncbi.nlm.nih.gov/17050875
https://pubmed.ncbi.nlm.nih.gov/17050875
Autor:
P. Molloy, Robert J. Mayer, Philip J. Stella, Philip J. Gold, Allen Lee Cohn, Andrew William Pippas, P. Windt, E. Van Cutsem, H. J. Lenz
Publikováno v:
European Journal of Cancer Supplements. 2:85-86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db92125009dc87e4596d76d7a6874792
https://doi.org/10.1016/s1359-6349(04)80287-8
https://doi.org/10.1016/s1359-6349(04)80287-8
Autor:
Allen Lee Cohn, Robert J. Mayer, P. Windt, H. J. Lenz, E. Van Cutsem, B. Mirtsching, Andrew William Pippas
Publikováno v:
Journal of Clinical Oncology. 23:3536-3536
3536 Background: Erbitux (Cetuximab), an IgG1 monoclonal antibody, is active in patients with metastatic colorectal cancer (CRC). A phase II study explored the activity of cetuximab in patients wit...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c33324464f011d533f58b76ae1ff248
https://doi.org/10.1200/jco.2005.23.16_suppl.3536
https://doi.org/10.1200/jco.2005.23.16_suppl.3536
Autor:
Robert J. Mayer, E. Van Cutsem, Philip J. Stella, Philip J. Gold, H. J. Lenz, Allen Lee Cohn, N. Azarnia, B. Mirtsching, Andrew William Pippas, M. N. Needle
Publikováno v:
Journal of Clinical Oncology. 22:3510-3510
3510 Background: Cetuximab (Erbitux) has demonstrated activity in patients with epidermal growth factor receptor (EGFR) expressing colorectal cancer (CRC) refractory to irinotecan (CPT-11) both as a single agent and in combination with irinotecan. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b6b8b1cdec77632b885caa4109a5f00
https://doi.org/10.1200/jco.2004.22.90140.3510
https://doi.org/10.1200/jco.2004.22.90140.3510